Analysis and comparison of somatic mutations in paired primary and recurrent epithelial ovarian cancer samples

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Kim, Yong Man ^a,c   Lee, Shin Wha ^a,c   Chun, Sung Min ^a,c   Kim, Dae Yeon ^a   Kim, Jong Hyeok ^a   Kim, Kyu Rae ^a   Kim, Young Tak ^a   Nam, Joo Hyun ^a   Van Hummelen, Paul ^b   MacConaill, Laura E ^b   Hahn, William C ^b   Jang, Se Jin ^a,c  

^a University of Ulsan   (South Korea)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BCL2 RELATED PROTEIN A1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLOPHOSPHAMIDE; DOCETAXEL; K RAS PROTEIN; PACLITAXEL; PLATINUM; PROTEIN MLH1; PROTEIN P53; VASCULOTROPIN RECEPTOR; KRAS PROTEIN, HUMAN; MLH1 PROTEIN, HUMAN; NUCLEAR PROTEIN; ONCOPROTEIN; RAS PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TP53 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CDKN2A GENE; COMPARATIVE STUDY; CONTROLLED STUDY; EPIGENETICS; FEMALE; GENE; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HIGH THROUGHPUT SEQUENCING; HUMAN; MLH1 GENE; ONCOGENE K RAS; OVARY CARCINOMA; POINT MUTATION; PRIMARY TUMOR; PROGNOSIS; SOMATIC MUTATION; TP53 GENE; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASM; NUCLEOTIDE SEQUENCE; OVARY TUMOR; PATHOLOGY; SECONDARY; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; COLORECTAL NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84903292663     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099451     Document Type: Article

References (31)

1. Boring CC, Squires TS, Tong T (1991) Cancer Statistics, 1991. CA Cancer J Clin 41: 19-36.
2. Liu J, Matulonis UA (2010) New advances in ovarian cancer. Oncology (Williston Park) 24: 721-728.
3. Bookman MA, Brady MF, McGuire WP, Harper PG, Alberts DS, et al. (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27: 1419-1425.
4. Weinstein IB (2002) Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297: 63-64.
5. Bast RC Jr, Hennessy B, Mills GB (2009) The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 9: 415-428.
6. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615.
7. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, et al. (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39: 347-351. (Pubitemid 46328493)
8. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, et al. (2009) Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. PLoS One 4: e7887.
9. Maeng CH, Lee J, van Hummelen P, Park SH, Palescandolo E, et al. (2012) High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and BRAF mutations. PLoS One 7: e41655.
10. Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu J, et al. (2011) High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One 6: e24433.
11. Choy E, Hornicek F, Macconaill L, Harmon D, Tariq Z, et al. (2012) High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer 118: 2905-2914.
12. Lee J, van Hummelen P, Go C, Palescandolo E, Jang J, et al. (2012) High-throughput mutation profiling identifies frequent somatic mutations in advanced gastric adenocarcinoma. PLoS One 7: e38892.
13. Goh AM, Coffill CR, Lane DP (2011) The role of mutant p53 in human cancer. J Pathol 223: 116-126.
14. Ahmed AA, Etemadmoghadam D, Temple J, Lynch AG, Riad M, et al. (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221: 49-56.
15. Pal T, Akbari MR, Sun P, Lee JH, Fulp J, et al. (2012) Frequency of mutations in mismatch repair genes in a population-based study of women with ovarian cancer. Br J Cancer 107: 1783-1790.
16. Zhang R, Qin W, Xu GL, Zeng FF, Li CX (2012) A meta-analysis of the prevalence of somatic mutations in the hMLH1 and hMSH2 genes in colorectal cancer. Colorectal Dis 14: e80-89.
17. Auner V, Kriegshäuser G, Tong D, Horvat R, Reinthaller A, et al. (2009) KRAS mutation analysis in ovarian samples using a high sensitivity biochip assay. BMC Cancer 9: 111.
18. Endo K, Sasaki H, Yano M, Kobayashi Y, Yukiue H, et al. (2006) Evaluation of the epidermal growth factor receptor gene mutation and copy number in nonsmall cell lung cancer with gefitinib therapy. Oncol Rep 16: 533-541.
19. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, et al. (2008) Kras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359: 1757-1765.
20. Hunter SM, Gorringe KL, Christie M, Rowley SM, Bowtell DD, et al. (2012) Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrations. Clin Cancer Res 18: 5267-5277.
21. Thompson AM, Jordan LB, Quinlan P, Anderson E, Skene A, et al. (2010) Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS). Breast Cancer Res 12: R92.
22. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K (2008) Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99: 929-935. (Pubitemid 351997594)
23. Park S, Holmes-Tisch AJ, Cho EY, Shim YM, Kim J, et al. (2009) Discordance of molecular biomarkers associated with epidermal growth factor receptor pathway between primary tumors and lymph node metastasis in nonsmall cell lung cancer. J Thorac Oncol 4: 809-815.
24. Gow CH, Chang YL, Hsu YC, Tsai MF, Wu CT, et al. (2009) Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol 20: 696-702.
25. Nakano H, Soda H, Takasu M, Tomonaga N, Yamaguchi H, et al. (2008) Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. Lung Cancer 60: 136-140. (Pubitemid 351434456)
26. Li ZH, Zheng J, Weiss LM, Shibata D (1994) C-k-ras and p53 mutations occur very early in adenocarcinoma of the lung. Am J Pathol 144: 303-309. (Pubitemid 24165951)
27. Yatabe Y, Matsuo K, Mitsudomi T (2011) Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma. J Clin Oncol 29: 2972-2977.
28. Surowiak P, Materna V, Kaplenko I, Spaczynski M, Dietel M, et al. (2006) Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples. Histol Histopathol 21: 713-720. (Pubitemid 44082713)
29. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, et al. (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93: 98-106. (Pubitemid 38429555)
30. Zajchowski DA, Karlan BY, Shawver LK (2012) Treatment-related protein biomarker expression differs between primary and recurrent ovarian carcinomas. Mol Cancer Ther 11: 492-502.
31. Zhang J, Shi Y, Lalonde E, Li L, Cavallone L, et al. (2013) Exome profiling of primary, metastatic and recurrent ovarian carcinomas in a BRCA1-positive patient. BMC Cancer 13: 146.